在新诊断的多发性骨髓瘤中对达拉图穆马布,环胺,thalidomide和dexamethasone进行了2期试验
Edvan de Queiroz Crusoé1,2, Joanna Suzana Leal Ribeiro Dos Santos2, Juliana de Andrade Santos1,2
1Hospital Universitário Professor Edgar Santos, Federal University of Bahia, Hematology and Hemotherapy Department, Salvador, Brazil.
Blood neoplasia
|June 27, 2025
概括
达拉-CTD疗法,包括达拉图穆马布,环胺,沙利多米德和德克萨梅他,在新诊断的多发性骨髓瘤患者中显示出高疗效,符合干细胞移植的条件. 这种无蛋白酶体抑制剂的治疗实现了75%的非常好的部分反应率,并具有可接受的安全性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 新诊断的多发性骨髓瘤 (NDMM) 治疗通常涉及将抗CD38单克隆抗体与各种药物结合起来.
- 蛋白质酶抑制剂 (PI),基剂和皮质类固醇是NDMM治疗方案中的标准成分.
研究的目的:
- 评估达拉图穆马布,环胺,沙利多米德和德克萨米 (Dara-CTD) 治疗方案在符合自主干细胞移植 (ASCT) 资格的NDMM患者中的疗效和安全性.
主要方法:
- 共有24名NDMM患者接受了4个周期的Dara-CTD诱导,随后进行ASCT.
- 巩固疗法包括达拉图穆马布和沙利多米德 (Dara-TD) 的4个周期,随后是单剂达拉图穆马布维护.
- 主要终点是巩固后非常好的部分响应 (VGPR) 率;无进展生存率 (PFS) 是一个关键的次要终点.
主要成果:
- 在75.0%的患者中,Dara-CTD疗法实现了VGPR或更好的VGPR.
- 没有达到中位响应持续时间,响应持续时间为9.5至41.9个月.
- 估计36个月的PFS为65%,48个月的整体存活率为70%.
结论:
- 达拉-CTD疗法是一种有效的,无蛋白酶体抑制剂的四重疗法,适用于ASCT合格的NDMM患者.
- 治疗表明可接受的安全性,可控的毒性.
- 这种疗法为在ASCT之前的NDMM治疗提供了一个有希望的替代方案.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
14.7K
相关概念视频
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
01:16Clinical Trials
8.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.7K